Literature DB >> 30347105

Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy.

Lloyd Paul Aiello1, Isoken Odia2, Adam R Glassman2, Michele Melia2, Lee M Jampol3, Neil M Bressler4,5, Szilard Kiss6, Paolo S Silva1, Charles C Wykoff7, Jennifer K Sun1,8.   

Abstract

Importance: Moderate to substantial agreement between Early Treatment Diabetic Retinopathy Study (ETDRS) 7-field imaging and ultrawide-field (UWF) imaging has been suggested in single-center studies. Comparing images obtained by multiple centers could increase confidence that UWF images can be used reliably in place of ETDRS imaging in future clinical trials. Objective: To compare diabetic retinopathy (DR) severity from modified ETDRS 7-field imaging and UWF imaging. Design, Setting, and Participants: This preplanned, cross-sectional analysis included modified ETDRS 7-field images obtained using the Diabetic Retinopathy Clinical Research Network acquisition protocol and UWF images obtained captured with the Optos 200Tx system (Optos, PLC) from adult participants (≥18 years old) with type 1 or type 2 diabetes. Both image types were evaluated by trained graders masked to clinical data. Data collection occurred from February 2015 to December 2015, and data analysis from June 2016 to December 2017. Main Outcomes and Measures: Agreement between UWF images, UWF images masked to include only the ETDRS 7-field area, and ETDRS 7-field images were calculated using κ statistics.
Results: A total of 764 eyes from 385 participants were included; participants had a median (IQR) age of 62.2 (53.6-69.2) years, 194 (50.4%) were women, and 256 (66.5%) were white. Of 742 eyes with both ETDRS 7-field images and UWF masked images graded, 359 (48.4% [95% CI, 44.4%-52.4%]) eyes had exact agreement, and 653 eyes (88.0% [95% CI, 85.2%-90.3%]) agreed within 1 step (weighted κ, 0.51 [95% CI, 0.44-0.58]). After open adjudication by an independent senior grader of all images with more than a 2-step discrepancy, perfect agreement was found in 435 eyes (59.0% [95% CI, 55.1%-62.8%]) and agreement within 1 step in 714 eyes (96.9% [95% CI, 95.1%-98.0%]; κ, 0.77 [95% CI, 0.73-0.82]). Ability of the imaging modalities to detect retinopathy severity in an individual eye was considered similar in 59 eyes (50.9% [95% CI, 41.3%-60.4%]), better for ETDRS 7-field imaging in 22 eyes (19.0% [95% CI, 12.5%-27.7%]), and better for UWF-masked images in 31 eyes (26.7% [95% CI 18.8%-36.5%]). Comparing UWF masked and unmasked images, 94 of 751 eyes (12.5%) had DR graded as at least 1 step more severe on UWF unmasked images vs UWF masked images. Predominantly peripheral DR lesions were present in 308 of 751 eyes (41.0%); this suggested increased DR severity by 2 or more steps in 34 eyes (11.0%). Conclusions and Relevance: Imaging by the ETDRS 7-field and UWF imaging systems have moderate to substantial agreement when determining the severity of DR within the 7 standard fields. Disparities in an individual eye are equivalently distributed between imaging modalities and can be better or worse on 1 or the other. Longitudinal follow-up will evaluate the primary outcome of this study to determine if peripheral retinal findings are associated with future retinopathy outcomes.

Entities:  

Mesh:

Year:  2019        PMID: 30347105      PMCID: PMC6439787          DOI: 10.1001/jamaophthalmol.2018.4982

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   8.253


  16 in total

1.  Real-Time Ultrawide Field Image Evaluation of Retinopathy in a Diabetes Telemedicine Program.

Authors:  Paolo S Silva; Jerry D Cavallerano; Ann M Tolson; Jessica Rodriguez; Sashida Rodriguez; Radwan Ajlan; Dorothy Tolls; Bina Patel; Mina Sehizadeh; Komal Thakore; Jennifer K Sun; Lloyd Paul Aiello
Journal:  Diabetes Care       Date:  2015-06-01       Impact factor: 19.112

2.  Nonmydriatic ultrawide field retinal imaging compared with dilated standard 7-field 35-mm photography and retinal specialist examination for evaluation of diabetic retinopathy.

Authors:  Paolo S Silva; Jerry D Cavallerano; Jennifer K Sun; Jason Noble; Lloyd M Aiello; Lloyd Paul Aiello
Journal:  Am J Ophthalmol       Date:  2012-05-23       Impact factor: 5.258

3.  Quantification of the image obtained with a wide-field scanning ophthalmoscope.

Authors:  Akio Oishi; Jiro Hidaka; Nagahisa Yoshimura
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-15       Impact factor: 4.799

4.  Midperipheral fundus involvement in diabetic retinopathy.

Authors:  K Shimizu; Y Kobayashi; K Muraoka
Journal:  Ophthalmology       Date:  1981-07       Impact factor: 12.079

5.  Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

6.  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

7.  Peripheral lesions identified by mydriatic ultrawide field imaging: distribution and potential impact on diabetic retinopathy severity.

Authors:  Paolo S Silva; Jerry D Cavallerano; Jennifer K Sun; Ahmed Z Soliman; Lloyd M Aiello; Lloyd Paul Aiello
Journal:  Ophthalmology       Date:  2013-06-15       Impact factor: 12.079

8.  Comparison between Early Treatment Diabetic Retinopathy Study 7-field retinal photos and non-mydriatic, mydriatic and mydriatic steered widefield scanning laser ophthalmoscopy for assessment of diabetic retinopathy.

Authors:  Malin L Rasmussen; Rebecca Broe; Ulrik Frydkjaer-Olsen; Birthe S Olsen; Henrik B Mortensen; Tunde Peto; Jakob Grauslund
Journal:  J Diabetes Complications       Date:  2014-08-28       Impact factor: 2.852

9.  Optomap ultrawide field imaging identifies additional retinal abnormalities in patients with diabetic retinopathy.

Authors:  Liam D Price; Stephanie Au; N Victor Chong
Journal:  Clin Ophthalmol       Date:  2015-03-24

10.  Assessment of diabetic retinopathy using nonmydriatic ultra-widefield scanning laser ophthalmoscopy (Optomap) compared with ETDRS 7-field stereo photography.

Authors:  Marcus Kernt; Indrawati Hadi; Florian Pinter; Florian Seidensticker; Christoph Hirneiss; Christos Haritoglou; Anselm Kampik; Michael W Ulbig; Aljoscha S Neubauer
Journal:  Diabetes Care       Date:  2012-08-21       Impact factor: 19.112

View more
  30 in total

1.  Quantification of Retinal Nonperfusion and Neovascularization With Ultrawidefield Fluorescein Angiography in Patients With Diabetes and Associated Characteristics of Advanced Disease.

Authors:  Gina Yu; Michael T Aaberg; Tapan P Patel; Rahul S Iyengar; Corey Powell; Annie Tran; Caitlin Miranda; Emma Young; Katarina Demetriou; Laxmi Devisetty; Yannis M Paulus
Journal:  JAMA Ophthalmol       Date:  2020-06-01       Impact factor: 7.389

2.  Distribution of peripheral lesions identified by mydriatic ultra-wide field fundus imaging in diabetic retinopathy.

Authors:  Aditya Verma; Ahmed Roshdy Alagorie; Kim Ramasamy; Jano van Hemert; N K Yadav; Rajeev R Pappuru; Adnan Tufail; Muneesawar Gupta Nittala; SriniVas R Sadda; Rajiv Raman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-01-27       Impact factor: 3.117

3.  Two-Year Incidence of Retinal Intervention in Patients With Minimal or No Diabetic Retinopathy on Telemedicine Screening.

Authors:  Bobeck S Modjtahedi; Christos Theophanous; Stephan Chiu; Tiffany Q Luong; Natasha Nguyen; Donald S Fong
Journal:  JAMA Ophthalmol       Date:  2019-04-01       Impact factor: 7.389

Review 4.  Imaging and Biomarkers in Diabetic Macular Edema and Diabetic Retinopathy.

Authors:  Changyow C Kwan; Amani A Fawzi
Journal:  Curr Diab Rep       Date:  2019-08-31       Impact factor: 4.810

Review 5.  Pediatric Diabetic Retinopathy: Updates in Prevalence, Risk Factors, Screening, and Management.

Authors:  Tyger Lin; Rose A Gubitosi-Klug; Roomasa Channa; Risa M Wolf
Journal:  Curr Diab Rep       Date:  2021-12-13       Impact factor: 4.810

6.  Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time.

Authors:  Paolo S Silva; Dennis M Marcus; Danni Liu; Lloyd Paul Aiello; Andrew Antoszyk; Michael Elman; Scott Friedman; Adam R Glassman; Joseph M Googe; Lee Merrill Jampol; Daniel F Martin; Michele Melia; Carin M Preston; Charles C Wykoff; Jennifer K Sun
Journal:  JAMA Ophthalmol       Date:  2022-10-01       Impact factor: 8.253

7.  Interaction Between the Distribution of Diabetic Retinopathy Lesions and the Association of Optical Coherence Tomography Angiography Scans With Diabetic Retinopathy Severity.

Authors:  Mohamed Ashraf; Konstantina Sampani; Abdulrahman Rageh; Paolo S Silva; Lloyd Paul Aiello; Jennifer K Sun
Journal:  JAMA Ophthalmol       Date:  2020-12-01       Impact factor: 7.389

8.  Updating the Staging System for Diabetic Retinal Disease.

Authors:  Jennifer K Sun; Lloyd Paul Aiello; Michael D Abràmoff; David A Antonetti; Sanjoy Dutta; Marlon Pragnell; S Robert Levine; Thomas W Gardner
Journal:  Ophthalmology       Date:  2020-11-17       Impact factor: 12.079

9.  Factors Affecting Predominantly Peripheral Lesion Identification and Grading.

Authors:  Mohamed Ashraf; Abdulrahman Rageh; Michael Gilbert; Dorothy Tolls; Alan Fleming; Ahmed Souka; Samir El-Baha; Jerry D Cavallerano; Jennifer K Sun; Lloyd Paul Aiello; Paolo S Silva
Journal:  Transl Vis Sci Technol       Date:  2021-06-01       Impact factor: 3.048

Review 10.  Recently updated global diabetic retinopathy screening guidelines: commonalities, differences, and future possibilities.

Authors:  Taraprasad Das; Brijesh Takkar; Sobha Sivaprasad; Thamarangsi Thanksphon; Hugh Taylor; Peter Wiedemann; Janos Nemeth; Patanjali D Nayar; Padmaja Kumari Rani; Rajiv Khandekar
Journal:  Eye (Lond)       Date:  2021-05-11       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.